Investigational drug · Phase 3
Abelacimab
Also called: MAA868
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atrial Fibrillation (AF), Stroke.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "Abelacimab"
First trial start
2021
Feb 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Abelacimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation (AF)
- Stroke
Approved drugs for the same conditions: Atrial fibrillation · Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Abelacimab" as an intervention, largest first.
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Pivotal-lookingRecruiting
Anthos Therapeutics, Inc.Industry
NCT05712200 · 2,500 participants (planned) · Start Dec 27, 2022 · Primary completion Dec 30, 2027
Drug: Abelacimab; Placebo · For: Atrial Fibrillation (AF)
Sites: Birmingham, Alabama; Mobile, Alabama; Gilbert, Arizona · 789 sites in all
- Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AnticoagulationPivotal-lookingNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07739888 · 2,500 participants (planned) · Start Dec 30, 2027 · Primary completion Dec 30, 2030
Drug: Abelacimab · For: Atrial Fibrillation (AF)
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Anthos Therapeutics, Inc.Industry
NCT04755283 · 1,287 participants · Start Feb 2, 2021 · Primary completion Feb 15, 2024
Drug: Abelacimab; Rivaroxaban · For: Atrial Fibrillation (AF); Stroke
Sites: Huntsville, Alabama; Mobile, Alabama; Stamford, Connecticut · 92 sites in all
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTEPivotal-lookingTerminated
Anthos Therapeutics, Inc.Industry
NCT05171049 · 1,150 participants · Start May 5, 2022 · Primary completion Feb 4, 2026
Drug: Abelacimab; Apixaban · For: Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism
Sites: Aurora, Colorado; West Haven, Connecticut; Washington D.C., District of Columbia · 209 sites in all
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTEPivotal-lookingTerminated
Anthos Therapeutics, Inc.Industry
NCT05171075 · 417 participants · Start Sep 27, 2022 · Primary completion Apr 10, 2026
Drug: Abelacimab; Dalteparin · For: Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism
Sites: Washington D.C., District of Columbia; Evanston, Illinois; St Louis, Missouri · 117 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro.
Guo X, Fredenburgh JC, Weitz JI · J Thromb Haemost 2026
- Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.
Kidder E, Dhanesha N · Curr Opin Hematol 2026
- FXIa inhibitors and secondary stroke prevention.
Palaiodimou L, Theodorou A, Stefanou MI, et al. · Curr Opin Neurol 2026
- Identification of Plasma Protein Biomarkers for Early-Onset Stroke through Mendelian Randomization.
Huynh AL, Gaynor BJ, Cole JW, et al. · medRxiv 2026
- Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm.
Al-Horani RA · ACS Pharmacol Transl Sci 2026
- A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.
Goubeau L, Curis E, Delavenne X, et al. · Blood Adv 2026
Also in development for Atrial Fibrillation (AF)
- REGN7508CenvacibartPhase 312 trials
Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism
- REGN9933amrecibartPhase 35 trials
Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)
- AP31969Phase 21 trial
Acesion Pharma · Atrial Fibrillation (AF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.